ClinicalTrials.gg
CompletedNCT02674321Updated Nov 9, 2021

A Pilot Study Of SD-809 (Deutetrabenazine) In Moderate To Severe Tourette Syndrome (TS)

A Phase 1 interventional study of SD-809 in TOURETTE SYNDROME, sponsored by Auspex Pharmaceuticals, Inc.. Completed at 1 site in United States. Open to participants aged 12 Years to 18 Years. Per ClinicalTrials.gov, last updated 2021-11-09.

Sponsored by Auspex Pharmaceuticals, Inc. (part of Teva Pharmaceutical Industries, Ltd.) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
23
Allocation
Not applicable
Ages
12 Years to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 139 studies in Tourette Syndrome with a site in United States — 20 open to participants now, 24 under way, 1 of them phase 3. Tourette Syndrome · United States.

Enrollment
63rd of 105
23 · median 33
Started
2014
with 8 others
Phase 1
9 of 139
none open now
Registered
73rd of 139
by date

Among the 139 studies in Tourette Syndrome with a site in United States, this one is the 63rd largest by enrollment of the 105 interventional ones that give a count, is one of 9 that started in 2014, is one of 9 in phase 1, and was the 73rd registered.

Tourette Syndrome

240 studies on the registry are indexed under Tourette Syndrome; 40 are open to participants now.

Browse Tourette Syndrome studies →

Open to participants now

20 of the 139 studies in Tourette Syndrome with a site in United States are open now. Recruiting first, the newest first:

15 more — sign in →

All 20 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 33 Tourette Syndrome studies recruiting now, 9 (27%) set no upper age limit and 22 (67%) stop at 75 or younger; 20 take children under 18; 9 take healthy volunteers.

This study: 12 Years to 18 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 139 studies in Tourette Syndrome with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate safety, tolerability and preliminary efficacy of SD-809 in the treatment of motor and phonic tics of Tourette Syndrome and to evaluate the pharmacokinetic of SD-809 and its metabolites.

03

Conditions studied

  • TOURETTE SYNDROME

Browse trials for

Keywords

  • Tourette Syndrome
  • adolescents
04

Who can participate

Ages eligible
12 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 12 to 18 years of age, inclusive, at Screening.
  • Patient has a , Fifth Edition (DSM-V) diagnosis of Tourette Syndrome and has manifested motor and phonic tics within 3 months before the Screening visit
  • Patient has total tic score of ≥19 on the YGTSS
  • Tic severity and frequency has been stable for at least 2 weeks before the Screening visit
  • Willing to adhere to medication regimen and to comply with all procedures
  • Patient is in good general health, as indicated by medical and psychiatric history and physical examination
  • Patient and parent/guardian have provided written, (and written assent, as appropriate)
  • Female patients of agree to use an acceptable method of

    • Additional criteria apply, please contact the investigator for more information

Exclusion criteria

Exclusion Criteria:

  • Patient has a serious untreated or undertreated psychiatric illness
  • Patient has a history of suicidal ideation or behavior
  • Patient has received tetrabenazine, neuroleptics, benzodiazepines, topiramate, dopamine receptor antagonists within 14 days of Screening or Baseline; or botulinum toxin within 3 months of Screening or Baseline
  • Patient is being treated with deep brain stimulation for control of tics
  • Patient has a progressive or degenerative neurological disorder or a structural disorder of the brain
  • Patient has participated in an drug or device trial within 30 days of Screening
  • Patient is pregnant or breastfeeding at Screening or Baseline
  • Patient has a history of alcohol or substance abuse in the previous 12 months, as defined in the

    • Additional criteria apply, please contact the investigator for more information
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
23 participants (actual)

Study arms

  • Experimental
    SD-809

    • SD-809 tablets taken once or twice daily for 8 weeks, includes a dose titration period and a maintenance period.

    Drug: SD-809

Interventions

06

What researchers measure

Primary outcomes

  1. Safety

    Incidence of adverse events (AEs), serious AEs, severe AEs, drug related AEs, AEs leading to withdrawal.

    Time frame: 8 weeks

Secondary outcomes

  1. Change from Baseline in Total Tic Score of the Yale Global Tic Severity Scale (YGTSS)

    Time frame: Baseline, Weeks 2, 4 and 8

  2. Change from Baseline in Impairment Score of the Yale Global Tic Severity Scale (YGTSS)

    Time frame: Baseline, Weeks 2, 4, and 8

  3. Change from Baseline in Global Severity Score of the Yale Global Tic Severity Scale (YGTSS)

    Time frame: Baseline, Weeks 2, 4, and 8

  4. Change from Baseline in Tourette Syndrome Clinical Global Impression

    Time frame: Baseline, Weeks 2, 4, and 8

  5. Patient Global Impression of Change (TS-PGIC)

    Time frame: Weeks 2, 4, and 8

Other outcomes

  1. Pharmacokinetic parameters

    Time frame: 8 weeks

07

Study locations

1 site
  • Teva Investigational Site #101
    Houston, Texas 77030, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2014, a primary completion of Jun 2015 and a completion of Jun 2015. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 2, 2016
First posted
Feb 4, 2016
Start
Jul 2014
Primary completionActual
Jun 2015
CompletionActual
Jun 2015
Last update
Nov 9, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 9, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02674321
Responsible party
Sponsor
First posted
Feb 4, 2016
Start date
Jul 2014
Primary completion
Jun 2015
Completion
Jun 2015
Last update
Nov 9, 2021

Study contacts

Teva Medical Expert, MD
study director · Teva Branded Pharmaceutical Products R&D, Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Deutetrabenazine

Start the discussion